Quarterly ResultMay 15, 2026, 07:41 AM
Sensei Biotherapeutics Q1 Net Loss $170.2M; PIKTOR Trial Initiated
AI Summary
Sensei Biotherapeutics reported a net loss of $170.2 million for the first quarter ended March 31, 2026, a significant increase from $6.9 million in the prior year, primarily due to $133.0 million in acquired IPR&D expenses related to the Faeth Therapeutics acquisition. The company's cash, cash equivalents, and marketable securities increased to $202.8 million, bolstered by a $200 million private placement. Sensei also provided a corporate update, including the dosing of the first patient in a Phase 1b/2 trial for PIKTOR in advanced breast cancer and anticipated topline Phase 2 data for PIKTOR in advanced endometrial cancer in the second half of 2026.
Key Highlights
- Net loss was $170.2 million for Q1 2026, compared to $6.9 million for Q1 2025.
- Cash, cash equivalents, and marketable securities were $202.8 million as of March 31, 2026, up from $21.2 million on December 31, 2025.
- Acquired In-Process Research and Development expenses were $133.0 million for Q1 2026.
- Research and Development expenses increased to $18.0 million for Q1 2026 from $3.7 million for Q1 2025.
- General and Administrative expenses rose to $19.7 million for Q1 2026 from $3.5 million for Q1 2025.
- First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer in April 2026.
- Topline Phase 2 data for PIKTOR in advanced endometrial cancer expected in second half 2026.
Price Impact
More from SNSE